Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen. “Until now nivolumab and the other anti-PD-1 and anti-PD-L1 drug...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2djtR22
via IFTTT